In October of 2009, Kumud Majumder, the father of an 11-year-old son with advanced leukemia, joined a lawsuit challenging the federal ban on compensating bone-marrow donors. He wanted to save his son's life. Last week Mr. Majumder and his co-plaintiffs enjoyed a victory. The U.S. Court of Appeals for the Ninth Circuit ruled that the majority of bone-marrow donors may lawfully be compensated.

The TSA should instruct its airport security workers to use common sense and discretion when putting people through the screening process.

The FDA must continue to pressure Chinese authorities to test what is on the market and remove any substandard products found.

The new health care law will create a policy limbo that is likely to persist for decades, increasing uncertainty, ultimately discouraging investment and scientific risk-taking.

Many of the 3.2 million Medicare patients who use home health services will be the first victims of health care rationing as a result of the Obama Health Care Reform Movement.

Price regulations are discouraginginnovation,and big drug makers are diverting capital away from research and development and pumping it into the less risky business of generic drugs.

Online communal wisdom should be harnessed for drug development.

Styrene's recent listing as "reasonably anticipated to be a human carcinogen" means something very different from how it is being framed by advocacy groups and the media—and this knowledge gap threatens to wreck legislative havoc across the country.